A biotool is a molecule that has been discovered, characterized, sometimes further developped, up to the level of a (or several) publication(s) or a patent(s), and with valuable informations on several key indicators such as target identity, high affinity/selectivity, functional effects in vitro, functional effects in vivo, compound availibility, physicochemical data, Pharmacokinetic data etc...
| Biotools name | Target nature |
|---|---|
| 3'dATP (or other dNTP) | polymérase/NS5 |
| SAH | méthyltransférase / NS5 |
| chalcone 4 | CXCL12 |
| ANA-12 | TrkB |
| bisacodyl | First described as cytotoxic to glioblastoma quiescent cells. Supposed to target WNK1 kinase pathway |
| PP-13 | Tubuline colchicine site |
| LPI 805 | NK2R tachykinin receptor |
| Liminib or Pyr1 | Lim Kinase |
| BDT001 | FLT3 |
| NMDI1 | NMD |
| ET-D5 | Protein Phosphatase 1 |
| Pyridocarbazole CK2-compound 18 | CK2 |
| C1 | Aurora kinases A/B |
| Retro-2.1 | intracellular pathogens |
| Daunorubicin | First identified as inhibiting MNBL1 and RNA (Muscleblind 1) |
| LIT-927 | CXCL12 ligand |
| GPN 136 | CCL22 |
| GPN 279 | CCL17 |
| cpd14 CCR5 ago | CCR5 |
| SRN 927 | CXCL12 |
| 2-amino-7-phenyldihydroquinazoline | unknown |
| M-030-E05 | E05 se fixe sur une protéine mitochondriale appelée apoptosis-inducing factor (AIF, 57kDa). |
| X55 | inhibition of CDA-deficient tumor cells |
| TB001 | TrkB |
| SR-FB-MPSBS018 | haspin |
| LIT-001 | Oxytocin receptor |
| tamoxifen | CDK5/p25 |
| meriolin 3 | Multitarget inhibitor of Cyclin-Dependent Kinases (CDKs) |
| indirubins: 6-bromoindirubin-3'-oxime (BIO) | GSK-3 (primary target) |
| DD264 | human DHODH |
| IPPA17-A04 or IPP/CNRS-A017 | human DHODH |
| A1B1C3_2 | glycerolipid synthase Toxoplasma gondii |
| A51B1C1_1 | Glycerolipids synthases |
| GAC50 | human DHODH |
| sr7575 | not known |
| MSK-1 inhibitor (4-(2-Chlorophenyl)-1H- benzo[d]imidazol-2-amine Hydrobromide) | MSK-1 (Mitogen- and Stress-Activated Kinase 1) |
| CRCM5484 | Bromodomain and extra-terminal (BET) bromodomains proteins with a 475-fold selectivity for the second bromodomain of the BRD3 protein (BRD3-BDII) over its first bromodomain (BRD3-BDI) |